Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival

Why Oncology Relies on Surrogates

Overall survival — how long patients live — is the outcome that matters most in cancer, but proving a survival benefit can take many years and large trials. To bring effective therapies to patients faster, oncology has developed a set of surrogate endpoints: earlier, measurable markers that aim to predict eventual clinical benefit. Understanding these surrogates is essential to reading oncology readouts.

The Three Endpoints You Must Know

• Overall Survival (OS). The gold-standard hard endpoint — time from randomization to death. Unambiguous and clinically definitive, but slow to mature.
• Progression-Free Survival (PFS). Time until the cancer grows or the patient dies. PFS reads out earlier than OS and is a widely used Phase 3 primary endpoint. Its strength as a surrogate for OS varies by tumor type.
• Objective Response Rate (ORR). The percentage of patients whose tumors shrink by a defined amount. ORR reads out earliest and is often the basis for Accelerated Approval, especially when paired with duration of response.

The general trade-off: ORR is fastest but furthest from the ultimate outcome; OS is definitive but slowest; PFS sits in between.

How Surrogates Map to Approvals

The endpoint a trial is built on shapes the regulatory path:

• A strong ORR in a single-arm study can support Accelerated Approval, with a confirmatory trial required to verify benefit — typically on PFS or OS.
• A PFS win in a randomized Phase 3 can support traditional approval in many settings.
• OS is the most durable basis for approval and the hardest for competitors and payers to dispute.

This is why the same drug can earn an accelerated approval on ORR, then convert to full approval once a survival or PFS benefit confirms it. Tracking that sequence is central to oncology due diligence.

The Risks Investors Must Weigh

The core risk with surrogates is that the surrogate can succeed while survival ultimately disappoints. A drug can shrink tumors or delay progression without patients living longer — because of crossover, subsequent therapies, or a benefit that simply doesn't translate.

Concrete implications:

1. Accelerated-approval drugs carry a confirmatory-readout overhang. A positive ORR-based approval is conditional on the later survival or PFS confirmation. A negative confirmatory trial can lead to withdrawal.
2. PFS-OS discordance happens. A strong PFS result that fails to translate into an OS benefit can undercut a label, payer coverage, and physician adoption.
3. The magnitude matters. A statistically significant but small PFS gain may not be clinically meaningful enough to drive uptake — significance and clinical relevance are different questions.

Reading an Oncology Readout

When an oncology trial reports, work through:

• Which endpoint was primary — ORR, PFS, or OS — and did it hit with statistical significance?
• What's the effect size? A hazard ratio and its confidence interval tell you the magnitude and precision of the benefit.
• Is OS supportive or immature? Early, immature OS data should be read cautiously; a clear OS trend strengthens the case.
• What's the confirmatory plan if the approval rests on a surrogate?

Applying It

For any oncology thesis, identify the surrogate the pivotal trial is built on and understand how predictive that surrogate has been in the relevant tumor type. An ORR-based Accelerated Approval is a different risk profile from an OS-based full approval — the first front-loads access but carries confirmatory risk, the second is slower but sturdier.

Track upcoming oncology Phase 3 readouts and FDA decisions on the catalyst calendar, and review each program — and the indications it targets — on the relevant company page. In oncology, the endpoint isn't a detail; it's the thesis.